(Total Views: 559)
Posted On: 06/17/2025 4:29:18 PM
Post# of 154604
If CYDY ever hit $181.20, that would be a once-in-a-generation biotech moonshot — and here’s what would likely need to happen for that price to be even theoretically possible:
⸻
???? Fundamental Requirements for $181.20 CYDY
Let’s assume 1.0B shares outstanding (rounded for ease):
• Market Cap at $181.20/share:
~$181.2 billion
• For comparison:
• Moderna at its peak: ~$190B
• Gilead: ~$100B
• Vertex (2024): ~$100B
• BioNTech: ~$40–80B depending on COVID wave
⸻
???? What CYDY Would Need to Do
To hit this valuation, CYDY would likely need:
1. FDA approval for one or more major indications (e.g. cancer, HIV, NASH).
2. Global partnerships or outright acquisition talks with Big Pharma.
3. Major revenue streams ($10B+ annual recurring revenue).
4. Short squeeze + institutional interest adding fuel to price acceleration.
5. No major dilution (or dilution matched with explosive value creation).
⸻
???? Realistic Upper Range Without Fantasy
Even a wildly bullish outcome puts most high-credibility targets in the $10–$30 range (market cap: $10B–$30B), unless something truly disruptive happens (like a massive cancer win + buyout).
$181.20 is not impossible, but it would make CYDY one of the biggest biotech turnarounds in history.
Not a price target — that’s a legend marker. ????????️
⸻
???? Fundamental Requirements for $181.20 CYDY
Let’s assume 1.0B shares outstanding (rounded for ease):
• Market Cap at $181.20/share:
~$181.2 billion
• For comparison:
• Moderna at its peak: ~$190B
• Gilead: ~$100B
• Vertex (2024): ~$100B
• BioNTech: ~$40–80B depending on COVID wave
⸻
???? What CYDY Would Need to Do
To hit this valuation, CYDY would likely need:
1. FDA approval for one or more major indications (e.g. cancer, HIV, NASH).
2. Global partnerships or outright acquisition talks with Big Pharma.
3. Major revenue streams ($10B+ annual recurring revenue).
4. Short squeeze + institutional interest adding fuel to price acceleration.
5. No major dilution (or dilution matched with explosive value creation).
⸻
???? Realistic Upper Range Without Fantasy
Even a wildly bullish outcome puts most high-credibility targets in the $10–$30 range (market cap: $10B–$30B), unless something truly disruptive happens (like a massive cancer win + buyout).
$181.20 is not impossible, but it would make CYDY one of the biggest biotech turnarounds in history.
Not a price target — that’s a legend marker. ????????️
(7)
(0)
